Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
15 October 2010Website:
http://www.iovance.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 15 Nov 2024 00:59:51 GMTDividend
Analysts recommendations
Institutional Ownership
IOVA Latest News
Iovance Biotherapeutics' Q3 earnings outperformed expectations, with $58.6m in revenue, but shares fell due to high market expectations and competition concerns. Amtagvi, Iovance's lead drug, shows strong commercial potential with 2025 revenue guidance of $450-$475m and significant opportunities in melanoma and other cancers including NSCLC. Despite high cash burn and competition, Iovance's growth in revenue, reimbursement, and treatment centers suggests a “buy the dip” opportunity for risk-tolerant investors.
Iovance reports better-than-expected third-quarter results. Management maintains its previously issued guidance for product revenues for full-year 2024 and 2025.
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.46 per share a year ago.
SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its third quarter and year to date 2024 financial results on Thursday, November 7, 2024.
With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout.
The biotech is making important breakthroughs, but is that enough?
Iovance Biotherapeutics' Amtagvi has gained rapid market traction post-FDA approval, with strong Q3 performance and promising revenue projections for 2024 and beyond. The company's growth prospects are bolstered by potential regulatory approvals in international markets and ongoing trials in other cancer types, including NSCLC. Despite the positive outlook, risks include market penetration challenges, regulatory hurdles, competition, and financial sustainability concerns due to ongoing cash burn.
Iovance Biotherapeutics is laying the groundwork to start realizing lots of revenue. It also has a lot of work in progress to increase the number of patients it can help.
Iovance Biotherapeutics will take some time to become profitable. It will probably see its medicine approved in more places before that happens.
Iovance Biotherapeutics obtained accelerated approval for its cell therapy, Amtagvi, earlier this year. The company has begun rolling it out, and it presents a big opportunity for the business.
What type of business is Iovance Biotherapeutics?
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing products for cancer immunotherapy using the patient's own immune system to destroy cancer cells. The company utilizes its own manufacturing process for tumor therapy, which has reduced manufacturing time from 5-6 weeks to 22 days. In addition, Iovance Biotherapeutics is conducting a number of trials for the treatment of metastatic melanoma, cervical cancer, head and neck cancer, lung cancer, and other forms of cancer. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
What sector is Iovance Biotherapeutics in?
Iovance Biotherapeutics is in the Healthcare sector
What industry is Iovance Biotherapeutics in?
Iovance Biotherapeutics is in the Biotechnology industry
What country is Iovance Biotherapeutics from?
Iovance Biotherapeutics is headquartered in United States
When did Iovance Biotherapeutics go public?
Iovance Biotherapeutics initial public offering (IPO) was on 15 October 2010
What is Iovance Biotherapeutics website?
https://www.iovance.com
Is Iovance Biotherapeutics in the S&P 500?
No, Iovance Biotherapeutics is not included in the S&P 500 index
Is Iovance Biotherapeutics in the NASDAQ 100?
No, Iovance Biotherapeutics is not included in the NASDAQ 100 index
Is Iovance Biotherapeutics in the Dow Jones?
No, Iovance Biotherapeutics is not included in the Dow Jones index
When was Iovance Biotherapeutics the previous earnings report?
No data
When does Iovance Biotherapeutics earnings report?
The next expected earnings date for Iovance Biotherapeutics is 28 February 2025